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Abstract
Background: Dementia is a progressive neurocognitive disease with a substantial social burden. No apparent
breakthroughs in treatment options have emerged so far; thus, disease prevention is essential for at-risk
populations. Depression and cerebrovascular disease (CVD) are independent risk factors for dementia, but no
studies have examined their interaction effect on dementia risk. This study aimed to identify the association of
depression and CVD with the risk of dementia and evaluate whether dementia risk among patients with comorbid
depression and CVD is higher than the sum of the individual risk due to each condition.
Methods: A population-based cohort study was conducted to analyze the Korean National Health Insurance
Service-National Sample Cohort data of all individuals over 50 years of age. Individuals who had not been
diagnosed with dementia at baseline were included and followed up from January 1, 2005, to December 31, 2013.
A time-varying Cox proportional hazard regression model adjusted for potential confounding factors was used for
the analysis. The interaction between depression and CVD was estimated based on the attributable proportion (AP),
relative excess risk due to interaction (RERI), synergy index (SI), and multiplicative-scale interaction.
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Results: A total of 242,237 participants were included in the analytical sample, of which 12,735 (5.3%) developed
dementia. Compared to that for participants without depression or CVD, the adjusted hazard ratio for the incidence
of dementia for those with depression alone was 2.35 (95% confidence interval [CI] 2.21–2.49), CVD alone was 3.25
(95% CI 3.11–3.39), and comorbid depression and CVD was 5.02 (95% CI 4.66–5.42). The additive interaction
between depression and CVD was statistically significant (AP—0.08, 95% CI 0.01–0.16; RERI—0.42, 95% CI 0.03–0.82;
SI—1.12, 95% CI 1.01–1.24). The multiplicative interaction was significant too, but the effect was negative (0.66, 95%
CI 0.60–0.73).
Conclusions: In this population-based nationwide cohort with long-term follow-up, depression and CVD were
associated with an increased risk of dementia, and their coexistence additively increased dementia risk more than
the sum of the individual risks.
Keywords: Dementia, Depression, Cerebrovascular disease, Alzheimer’s disease, Additive interaction, Risk factors,
Nationwide population, Cohort study
Background
Dementia is a neurodegenerative disease characterized
by progressive cognitive decline. It precludes patients
from carrying out daily life activities independently and
often has devastating effects on the lives of patients and
their caregivers. Although the prevalence and disease
burden of dementia are increasing [1], there have been
no apparent breakthroughs in terms of treatment op-
tions to date. Therefore, identifying at-risk populations
and providing tailored care are essential for cost-
effective public health management [2].
Depression has been suggested as a risk factor for de-
mentia. According to recent meta-analyses of several
epidemiological studies [3, 4], late-life depression is asso-
ciated with increased dementia risk. Some researchers
have proposed indirect evidence that the effect of
depression on dementia risk is altered by comorbid cere-
brovascular disease (CVD), which is typically character-
ized by cerebral ischemia and hemorrhage. In a recent
large-scale retrospective study that included 35,791 indi-
viduals with 13 years of follow-up, depression was found
to have an exceptionally significant effect on dementia in
individuals with incident stroke [5]. A systemic review
has reported that cognitive decline in late-life depression
is associated with vascular dysfunction, including white
matter hyperintensity [6]. Reciprocally, risk factors for
dementia in patients with CVD also include depressive
illness [7]. Armstrong et al. conducted a longitudinal
study and reported that late-life depression partially me-
diates the association between cardiovascular disease
and cognitive decline [8].
However, the interaction effect of depression and
CVD, that is, whether one disease strengthens the asso-
ciation of another with dementia risk, remains unclear.
In contrast to dementia, the prevention and treatment of
these two illnesses have been well established and are
known to be effective [9, 10]. Therefore, clarifying the
interaction effect between depression and CVD on
dementia risk can help identify individuals who can
benefit more from a health care service at the same cost.
In the current study, we sought to evaluate the associ-
ation of depression and CVD with subsequent dementia
using a nationwide population-based cohort. We also
aimed to investigate whether the interaction between the
two conditions is additively associated with increased de-
mentia risk. As the epidemiology of depression, CVD,
and dementia is dependent upon age and sex, we exam-
ined whether the interaction between depression and
CVD differed by age or sex.
Methods
Study population
We used the nationwide population-based South Korean
National Health Insurance Service-National Sample Co-
hort (NHIS-NSC) database [11], which contains the data
of approximately 1 million people (2.2% of the total Ko-
rean population) and uses systematic stratified random
sampling with proportional allocation within each
stratum (age, sex, insurance eligibility status, and income
level). As the National Health Insurance (NHI) program
requires mandatory health insurance for all Korean citi-
zens, the database is representative of the South Korean
population. All insurance claims are cataloged in this
system, and the medical information in the database is
provided exclusively by healthcare providers. Every NHI
member older than 40 years is eligible for biennial car-
diovascular health panel screening and cancer screening
for free or at a minimal cost depending on income [12].
Prior studies have validated the NHIS-NSC data for
some chronic diseases, including stroke and dementia
[13–16]. Yet, the validation of the International Classifi-
cation of Diseases, 10th revision (ICD-10) codes for de-
pression diagnosis has not been evaluated [17].
Of the 1,044,097 individuals who were enrolled in the
cohort during the baseline period (January 1, 2002, to
December 31, 2004), we included 244,920 individuals
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over the age of 50 years and then excluded 2683 who
had or received a dementia diagnosis during this period
(Fig. 1). We followed up the participants from the index
date (January 1, 2005) until December 31, 2013, or until
the date of dementia onset within that period, defined as
the follow-up period. Patient death and the end of the
follow-up were treated as censoring events in the ana-
lyses. During the follow-up period of up to 9 years, indi-
viduals were classified into the following four groups
based on their depression or CVD diagnosis: individuals
with neither depression nor CVD, those with depression
alone, those with CVD alone, and those with both de-
pression and CVD.
The final analyses included a total of 242,237 partici-
pants. The institutional review board of the Samsung
Medical Center, Seoul, South Korea, approved this study.
All data were anonymized and kept confidential, and
thus, the need for obtaining participant informed con-
sent was waived.
Exposure variables: depression and CVD
Depression was defined as the assignment of an ICD-10
code for depressive disorder (F32 or F33) and the docu-
mented administration of antidepressant medication
(Additional file 1: Table S1) from the first day of depres-
sion diagnosis during the follow-up period as previously
described [18–20]. CVD was defined as the assignment
of an ICD-10 code for CVD (I60–69) as a primary
diagnosis and two or more hospital visits during the
follow-up period [20]. Unlike the medications used for
depression or dementia, CVD medications are not exclu-
sive to the disease. Therefore, we defined CVD based on
the ICD codes and multiple hospital visits regardless of
the medications prescribed.
Outcome of interest: dementia
The primary outcome was overall survival free of de-
mentia. We defined dementia as the assignment of an
ICD-10 code for dementia (F00–03, G30–31) and the
documented administration of anti-dementia medication
(donepezil, rivastigmine, galantamine, or memantine)
during the follow-up period [18, 21, 22]. As mentioned
above, we excluded all cases with a dementia diagnosis
during the baseline period to focus on incident cases of
dementia. Dementia subtype was set as the secondary
outcome and was defined based on the initial ICD-10
code assigned on the first day of dementia diagnosis: F00
and G30 for Alzheimer’s disease (AD), F01 for vascular
dementia (VD), and F02-03 and G31 for other dementias
(non-AD or non-VD).
Covariates
All analyses were adjusted for potential confounding
variables—age, sex, residential area, income level, and
comorbidities—during the baseline period from 2002 to
2004. With regard to the residential area, the capital city
of South Korea and the surrounding metropolitan cities
Fig. 1 Study population flow diagram
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(Seoul, Incheon, Gyeonggi-do) were designated as the
“capital region”; all other regions were designated as
“non-capital regions.” Income levels were classified as
low (up to the 30th percentile), middle (30th to 70th
percentile), and high (70th to 100th percentile). The
ICD-10 codes from the Charlson comorbidity index,
which is used widely to adjust for the effects of comor-
bidities [23], were used. We defined the comorbidities
based on the ICD-10 codes for each disease (Additional
file 1: Table S2) and two or more hospital visits during
the baseline period.
Interaction measurements
We assessed additive- and multiplicative-scale inter-
action measures to examine the interaction effect of de-
pression and CVD on dementia onset. In terms of the
additive interaction, we derived the attributable propor-
tion due to interaction [AP; Eq. (1)], relative excess risk
due to interaction [RERI; Eq. (2)], and synergy index [SI;
Eq. (3)]. The AP is the proportion of the risk due to the
interaction in the doubly exposed group (null hypoth-
esis: AP = 0). When RERI is positive, it indicates in-
creased risk due to the additive interaction (null
hypothesis: RERI = 0). SI can be interpreted as the ratio
of an increased risk due to both exposures to the sum of
individual increased risks (null hypothesis: SI = 1). These
were used to assess whether the risk due to having both
diseases is greater than the sum of the risks due to each
condition [24, 25].
APInteraction ¼ HRDepression&CVD −HRDepression −HRCVD þ 1HRDepression&CVD
ð1Þ
RERIInteraction ¼ HRDepression&CVD −HRDepression −HRCVD þ 1
ð2Þ
SIInteraction ¼ HRDepression&CVD − 1HRDepression þHRCVD − 2 ð3Þ
The multiplicative-scale interaction [Eq. (4)] has
been widely used to examine the interaction effects
by identifying whether the risk due to having both
diseases is greater than the product of the risks due
to each disease alone (null hypothesis: multiplicative
interaction = 1) [24, 25].
MultInteraction ¼ HRDepression&CVDHRDepression HRCVD ð4Þ
In Eqs. (1–4), HRDepression & CVD represents the hazard
ratio (HR) for those who have both depression and
CVD. HRDepression and HRCVD represent the HR for
those who have depression or CVD alone, respectively,
compared with individuals who have neither of the
conditions.
Statistical analysis
We used Cox proportional hazards regression models
to determine the adjusted hazard ratios (aHRs) and
95% confidence intervals (CIs) of depression, CVD, or
comorbid depression and CVD for dementia inci-
dence. As the cohort design can cause an immortal
time bias, we used a time-varying Cox regression
model to prevent time-related biases [26, 27]. An un-
adjusted time-varying Cox regression analysis was
performed (model 1), followed by a demographic
characteristics-adjusted (model 2; adjusted for age,
sex, residential area, and income level), and a
comorbidity-adjusted (model 3; adjusted for myocar-
dial infarction, congestive heart failure, peripheral vas-
cular disease, chronic pulmonary disease, connective
tissue disorder, peptic ulcer, mild liver disease, un-
complicated diabetes, complicated diabetes, hemiple-
gia, moderate or severe renal diseases, non-metastatic
solid cancer, moderate or severe liver diseases, and
metastatic solid cancer in addition to the demo-
graphic characteristics in model 2) analysis. The pro-
portional hazards assumption was graphically tested
and verified using the Schoenfeld residual method; no
variables violated the assumption.
First, we used a log-rank test and evaluated independ-
ent associations of depression and CVD with subsequent
dementia using aHRs and 95% CIs in two separate re-
gression models. In this analysis, exposure of interest
(depression or CVD) was treated as a time-varying vari-
able, and the other comorbid illnesses were regarded as
time-fixed confounders to be adjusted. Next, we exam-
ined the interaction effect of the two exposure diseases
by calculating the additive (AP, RERI, and SI) and multi-
plicative interaction. We verified the significance of the
interaction term and then stratified each subgroup based
on age or sex. The two-way interaction effect was tested
on independent associations of depression or CVD with
each subgroup, and the three-way interaction effect was
tested on interactive associations of depression and CVD
with each subgroup. We then conducted a subgroup
analysis using a fully adjusted Cox regression model
(model 3; demographic characteristics and comorbidities
adjusted) in which dementia subtypes (AD, VD, and
non-AD or non-VD) were accounted into the outcome
variables.
We also carried out sensitivity analyses to ensure
the robustness of the results. First, a lagged-time ana-
lysis was conducted because depression that occurs
shortly before dementia onset can be a prodrome of
dementia [28]. We classified individuals who were
newly diagnosed with depression during the lagged-
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time period into the “no depression” group. Second,
we repeated the analysis using ICD-10 code disease
definitions only. As the strict operational definitions
of depression, CVD, and dementia can lead to selec-
tion bias, we applied mitigated definitions regardless
of the medication prescriptions or the number of hos-
pital visits. All statistical analyses were performed
using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Participant characteristics and incidence of dementia
Participant characteristics are presented in Table 1. A
total of 242,237 participants were included in the ana-
lyses (77,587 [68.0%] aged over 65 years at baseline; 131,
712 [54.4%] women; 140,415 [58.0%] from non-capital
regions). A total of 7006 (2.9%) participants had histories
of depression during the baseline period, and 9680
Table 1 Descriptive characteristics of the study population
Study population With dementia Without dementia
N % N % N %
Total 242,237 100.0 12,735 100.0 229,502 100.0
Age
50 to 64 years 164,650 68.0 3345 26.3 161,305 70.3
Above 64 years 77,587 32.0 9390 73.7 68,197 29.7
Sex
Men 110,525 45.6 3982 31.3 106,543 46.4
Women 131,712 54.4 8753 68.7 122,959 53.6
Residential areaa
Capital region 101,822 42.0 4403 34.6 97,419 42.5
Non-capital region 140,415 58.0 8332 65.4 132,083 57.6
Income levelb
Low 65,730 27.1 3948 31.0 61,782 26.9
Middle 80,753 33.3 3683 28.9 77,070 33.6
High 95,754 39.5 5104 40.1 90,650 39.5
Comorbidities
Myocardial infarction 2332 1.0 156 1.2 2176 1.0
Congestive heart failure 8904 3.7 814 6.4 8090 3.5
Peripheral vascular disease 6661 2.8 575 4.5 6086 2.7
Chronic pulmonary disease 47,871 19.8 3232 25.4 44,639 19.5
Connective tissue disorder 11,761 4.9 881 6.9 10,880 4.7
Peptic ulcer 50,849 21.0 2984 23.4 47,865 20.9
Mild liver disease 22,914 9.5 1022 8.0 21,892 9.5
Uncomplicated diabetes 29,720 12.3 2209 17.4 27,511 12.0
Complicated diabetesc 11,717 4.8 933 7.3 10,784 4.7
Hemiplegia 1533 0.6 151 1.2 1382 0.6
Moderate or severe renal diseases 1476 0.6 96 0.8 1380 0.6
Non-metastatic solid cancerd 9382 3.9 435 3.4 8947 3.9
Moderate or severe liver diseases 754 0.3 17 0.1 737 0.3
Metastatic solid cancer 2805 1.2 51 0.4 2754 1.2
Depression 7006 2.9 652 5.1 6354 2.8
Cerebrovascular disease 9680 4.0 1007 7.91 8673 3.8
aIndividuals who resided in the capital city of South Korea and surrounding metropolitan cities (Seoul, Incheon, Gyeonggi-do) were classified as belonging to the
“capital region” and the others to the “non-capital region”
bIncome levels were divided into three groups: low (up to the 30th percentile), middle (30th to 70th percentile), and high (70th to 100th percentile) income
cDiabetes complicated with retinopathy, neuropathy, or renal disease
dNon-metastatic solid cancer, including leukemia, lymphoma, and multiple myeloma
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(4.0%) participants had a history of CVD during the
same period. The demographic characteristics of the
study participants and the diseases from the Charlson
comorbidity index were set as covariates (Table 1). Dur-
ing the follow-up period, 12,735 (5.3%) participants were
newly diagnosed with dementia (AD, 9729 [76.4%]; VD,
1306 [10.3%]; non-AD or non-VD, 1700 [13.3%]; Add-
itional file 1: Table S3). There were significant differ-
ences between the groups in terms of age, sex, income
level, and comorbidities (p value < 0.05).
When the patients were classified into the four cat-
egories as shown in Fig. 1, the number of patients with
newly diagnosed dementia was 7525 (4.0%) in the refer-
ence group (N = 190,255; 78.5%), 1336 (6.8%) in the de-
pression alone group (N = 19,692; 8.1%), 3099 (11.6%) in
the CVD alone group (N = 26,798; 11.1%), and 775
(14.1%) in the comorbid depression and CVD group
(N = 5492; 2.3%).
Independent associations of depression and CVD with
increased dementia risk
We found significant associations of depression and
CVD with the risk of dementia (Additional file 1: Figure
S1). In the time-varying Cox proportional hazard model
analysis, depression was associated with a 122% in-
creased risk of dementia (aHR 2.22, 95% CI 2.12–2.33;
Table 2, Fig. 2a) after adjusting for age, sex, residential
area, income level, and comorbid chronic diseases, com-
pared to participants without depression. The lagged-
time analyses showed that the effect of depression was
significant even after considering depression that oc-
curred within the lagged-time period up to 2 years as a
prodrome of dementia (Additional file 1: Table S4). The
analyses with CVD showed that it was associated with a
higher hazard for dementia onset (aHR 3.12, 95% CI
3.00–3.25; Table 2, Fig. 2b). Significant effect modifica-
tions were observed according to age and sex subgroups
in both the analyses for depression and CVD patients
(all p values for the two-way interactions between dis-
eases and age or sex were <0.0001). The association be-
tween depression and subsequent dementia was
especially high in those under the age of 65 and men,
and the same was observed for CVD (Table 2).
Interaction effect of depression and CVD on dementia risk
Compared to the no depression or CVD group, the de-
pression alone group (aHR 2.35, 95% CI 2.21–2.49),
CVD alone group (aHR 3.25, 95% CI 3.11–3.39), and co-
morbid depression and CVD group (aHR 5.02, 95% CI
4.66–5.42) were significantly associated with an in-
creased risk of dementia (Table 3). All indices of the
additive interaction were statistically significant with
positive values (AP 0.08, 95% CI 0.01–0.16; RERI 0.42,
95% CI 0.03–0.82; SI 1.12, 95% CI 1.01–1.24; Table 3
and Fig. 2c). When participants were classified according
to their dementia subtypes, significant additive inter-
action between depression and CVD was found with AD
(AP 0.09, 95% CI 0.00–0.18; RERI 0.41, 95% CI − 0.01–
0.83; SI 1.13, 95% CI 1.00–1.28; Table 3). VD or other
dementia were not associated with the additive inter-
action effect of the two diseases. The effect modification
by age was statistically insignificant. However, the inter-
action effect between depression and CVD changed with
sex and was significant (p value for the three-way inter-
action among diseases and sex was < 0.0001) only in
women (AP 0.12, 95% CI 0.03–0.21; RERI 0.53, 95% CI
0.11–0.95; SI 1.18, 95% CI 1.04–1.34; Table 3). The
multiplicative interaction was significant in every ana-
lysis, but the effect was negative (Table 3). The sensitiv-
ity analysis using disease definitions based on the ICD-
10 codes further supported the results (Additional file 1:
Table S5).
Discussion
In this analysis of a nationwide population-based cohort
of 242,237 participants aged over 50 years, depression
and CVD were independently associated with a more
than double the risk of dementia. After adjusting for
demographic factors and comorbidities, we found a posi-
tive additive interaction between depression and CVD
on dementia risk, and this interaction effect was signifi-
cant only in women. In the analyses with dementia sub-
types, the interaction effect was associated with AD.
Our results reinforce the claim that individuals with
depression or CVD are more vulnerable to subsequent
dementia. We replicated prior findings with a large
population-based sample and also tested the
generalizability of our results. In this study, the effect of
depression on incident dementia was found to be stron-
ger in individuals below the age of 65 years and men
than that in individuals above the age of 64 years and
women, respectively. Our finding that participants with
depression that appeared in middle age are more vulner-
able to subsequent dementia contradicts those of some
studies [29, 30] that have reported that late-life depres-
sion is more strongly associated with dementia than
mid-life depression. However, a few researchers have ar-
gued that early-onset (before the age of 65 years) depres-
sion may be a long-term risk factor for dementia [31].
Whether the effect of depression on dementia risk dif-
fers according to the age of onset or the duration of
morbidity is controversial and needs further investiga-
tion. The effect modifications of sex on depression as a
risk factor for AD reported by previous studies have also
been inconsistent [32]. According to a recent systematic
review [33], these discrepant findings may be accounted
for by methodological differences, such as those related
to the recruitment method (clinic-based or population-
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Table 2 Cox regression analysis for independent associations between depression/CVD and dementia
No depression Depression No CVD CVD
Total population 217,053 (89.6%) 25,184 (10.4%) 209,947 (86.7%) 32,290 (13.3%)
Dementia events 10,624 (4.9%) 2111 (8.4%) 8861 (4.2%) 3874 (12.0%)
Person-years 1,777,860 210,499 1,734,836 253,523
Incidence (events/1000 person-years) 5.98 10.03 5.11 15.28
Log-rank test (p value) < 0.0001 < 0.0001
Unadjusted HR in model 1 (95% CI) 1 [reference] 2.40 (2.29–2.51) 1 [reference] 4.36 (4.20–4.53)
aHR in model 2 (95% CI) a 1 [reference] 2.35 (2.24–2.46) 1 [reference] 3.26 (3.14–3.39)
aHR in model 3 (95% CI) b 1 [reference] 2.22 (2.12–2.33) 1 [reference] 3.12 (3.00–3.25)
Age 50 to 64 years 147,019 (89.3%) 17,631 (10.7%) 147,069 (89.3%) 17,851 (10.7%)
Dementia events 2591 (1.8%) 754 (4.3%) 2150 (1.5%) 1195 (6.8%)
Person-years 1,271,789 152,534 1,276,238 148,084
Incidence (events/1000 person-years) 2.04 4.94 1.68 8.07
Log-rank test (p value) < 0.0001 < 0.0001
Unadjusted HR in model 1 (95% CI) 1 [reference] 3.43 (3.16–3.72) 1 [reference] 6.82 (6.35–7.32)
aHR in model 2 (95% CI)a 1 [reference] 3.24 (2.99–3.52) 1 [reference] 6.84 (6.37–7.34)
aHR in model 3 (95% CI)b 1 [reference] 3.11 (2.86–3.37) 1 [reference] 6.54 (6.09–7.03)
Age above 64 years 70,034 (90.3%) 7553 (9.7%) 62,878 (81.0%) 14,709 (19.0%)
Dementia events 8033 (11.5%) 1357 (18.0%) 6711 (10.7%) 2679 (18.2%)
Person-years 506,071 57,965 458,597 105,439
Incidence (events/1000 person-years) 15.87 23.41 14.63 25.41
Log-rank test (p value) < 0.0001 < 0.0001
Unadjusted HR in model 1 (95% CI) 1 [reference] 2.06 (1.95–2.18) 1 [reference] 2.50 (2.39–2.62)
aHR in model 2 (95% CI)a 1 [reference] 2.04 (1.93–2.16) 1 [reference] 2.55 (2.43–2.66)
aHR in model 3 (95% CI)b 1 [reference] 1.92 (1.81–2.04) 1 [reference] 2.44 (2.33–2.56)
Men 102,043 (92.3%) 8482 (7.7%) 95,637 (86.5%) 14,888 (13.5%)
Dementia events 3388 (3.3%) 594 (7.0%) 2531 (2.7%) 1451 (9.6%)
Person-years 831,452 69,492 784,992 115,952
Incidence (events/1000 person-years) 4.07 8.55 3.22 12.51
Log-rank test (p value) < 0.0001 < 0.0001
Unadjusted HR in model 1 (95% CI) 1 [reference] 3.13 (2.87–3.42) 1 [reference] 5.69 (5.33–6.07)
aHR in model 2 (95% CI)a 1 [reference] 2.83 (2.60–3.09) 1 [reference] 4.15 (3.88–4.42)
aHR in model 3 (95% CI)b 1 [reference] 2.69 (2.46–2.93) 1 [reference] 3.99 (3.74–4.26)
Women 115,010 (87.3%) 16,702 (12.7%) 114,310 (86.8%) 17,402 (13.2%)
Dementia events 7236 (6.3%) 1517 (9.1%) 6330 (5.5%) 2423 (13.9%)
Person-years 946,408 141,007 949,844 137,571
Incidence (events/1000 person-years) 7.65 10.76 6.66 17.61
Log-rank test (p value) < 0.0001 < 0.0001
Unadjusted HR in model 1 (95% CI) 1 [reference] 1.97 (1.87–2.09) 1 [reference] 3.84 (3.67–4.03)
aHR in model 2 (95% CI)a 1 [reference] 2.19 (2.07–2.32) 1 [reference] 2.89 (2.76–3.03)
aHR in model 3 (95% CI)b 1 [reference] 2.07 (1.96–2.19) 1 [reference] 2.77 (2.64–2.91)
Abbreviations: aHR adjusted hazard ratio, CI confidence interval, CVD cerebrovascular disease, HR hazard ratio
aAdjusted for demographic characteristics (age, sex, residential area, and income level)
bAdjusted for demographic characteristics (age, sex, residential area, and income level), other exposure diseases, and 14 comorbidities (myocardial infarction,
congestive heart failure, peripheral vascular disease, chronic pulmonary disease, connective tissue disorder, peptic ulcer, mild liver disease, uncomplicated
diabetes, complicated diabetes, hemiplegia, moderate or severe renal diseases, non-metastatic solid cancer, moderate or severe liver diseases, and metastatic
solid cancer)
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based), follow-up duration, and measure of depression
used. The current results provide evidence that depres-
sion among men in a community-based population is
more strongly associated with increased dementia risk
than among women.
Individuals with CVD were more likely to be diag-
nosed with dementia, especially VD, with more than
three times the risk, which is in line with the previous
literature [34]. Moreover, CVDs in men and younger age
groups were more strongly associated with increased de-
mentia risk. This is consistent with previous studies
which reported that post-stroke dementia is more preva-
lent in men [35]. In large-scale population-based cohort
studies on the association of cardiovascular risk [36] and
blood pressure pattern [37] with cognitive function, re-
searchers have consistently reported that mid-life
Fig. 2 Survival curves for dementia onset according to exposure diseases. a Survival curves for dementia onset according to the exposure of
depression. b Survival curves for dementia onset according to the exposure of CVD. c Survival curves for dementia onset according to the
exposures of depression and CVD
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vascular disease has a more substantial effect on demen-
tia onset. Our findings highlight the importance of mid-
life as a critical period for later cognitive function.
We found that both additive and multiplicative inter-
actions of depression and CVD on dementia risk were
statistically significant. However, they showed the oppos-
ite effect. This phenomenon is understood as the con-
cept of “interaction continuum” [38]. The form of
interaction depends on the relative magnitude of the
probability of the outcome, since it is calculated based
on each baseline subgroup risk; therefore, the scale of
the risk (i.e., scale dependence) affects it. In our result,
on the risk difference scale, the effect of depression was
larger in the CVD group than in the non-CVD group
(risk differences 1.77 vs. 1.35). Moreover, the effect of
the CVD was larger for those who had depression than
for the non-depression group (risk differences 2.67 vs.
2.25). However, on the risk ratio scale, the effect of de-
pression was smaller in the CVD group than in the non-
CVD group (risk ratios 1.77 vs. 2.35). This is because the
baseline risks for the depression and CVD groups were
relatively high, making it unlikely that the observed risk
in the comorbid depression and CVD group would ex-
ceed the multiplication of these baseline risks (i.e.,
2.35 × 3.25 = 7.64). Nevertheless, the existence of a posi-
tive additive interaction in the absence of multiplicative
interaction is still meaningful [38]. VanderWeele and
Knol [39] also reported that additive interaction, rather
than multiplicative interaction, is more suitable and im-
portant to be assessed as a relevant public health meas-
ure because multiplicative-scale interaction without
scale-dependent consideration sometimes indicates the
Table 3 Interaction effect of depression and CVD on the risk of dementia onset





Depression CVD Depression and
CVD
APa RERIa SIa



















































































































Abbreviations: AD Alzheimer’s disease, AP attributable proportion due to interaction, CI confidence interval, CVD cerebrovascular disease, HR hazard ratio, RERI
relative excess risk due to interaction, SI synergy index, VD vascular dementia
aNull hypothesis for each interaction is AP = 0, RERI = 0, SI = 1, and multiplicative interaction = 1
bUnadjusted model
cAdjusted for demographic characteristics (age, sex, residential area, and income level)
dAdjusted for demographic characteristics (age, sex, residential area, and income level) and 14 comorbidities (myocardial infarction, congestive heart failure,
peripheral vascular disease, chronic pulmonary disease, connective tissue disorder, peptic ulcer, mild liver disease, uncomplicated diabetes, complicated diabetes,
hemiplegia, moderate or severe renal diseases, non-metastatic solid cancer, moderate or severe liver diseases, and metastatic solid cancer)
eSubgroup analysis for dementia subtype was based on model 3 (adjusted for demographic characteristics and 14 comorbidities) and conducted separately by
considering the other dementia subtypes as a competing risk
fIncludes dementia in other diseases classified elsewhere (F02), unspecified dementia (F03), other degenerative diseases of the nervous system, and not elsewhere
classified (G31)
gSubgroup analyses for age and sex were based on model 3 (adjusted for demographic characteristics and 14 comorbidities). Age or sex was not considered as a
covariate in each subgroup analysis
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wrong subgroup (in our case, “no depression nor CVD”
group, but not “depression” or “CVD” group) for inter-
vention or treatment. In this study, the negative multi-
plicative interaction effect may also be partially
explained by the operational definition of medication
use or multiple hospital visits (theoretically possible
therapeutic or protective effect from the simultaneous
presence of two diseases). Therefore, in terms of bio-
logical plausibility and from the public health perspec-
tive, a positive additive interaction seems more
reasonable than a negative multiplicative interaction in
the context of our study [40].
The positive additive interaction between depression
and CVD on dementia risk remained statistically signifi-
cant after adjusting for covariates. Although we cannot
clarify the underlying biological mechanisms based on
this study, one possible explanation is that each illness
exacerbates the other condition through biological and
psychosocial changes. We could not tell the severity of
each disease in our analyses, but generally, patients ac-
companied by another disease are likely to be in a more
severe condition and have poor outcomes. Stroke limits
patients’ activities of daily living and impairs their social
and cognitive functions. It frequently gives rise to a de-
pressed mood as a psychosocial reaction [41]. Vascular
damage in specific brain regions related to mood regula-
tion could make patients susceptible to depressive disor-
ders [42]. Besides, depression might affect patient health
behaviors and make them vulnerable to CVD through
HPA axis dysregulation or a chronic inflammatory state
[43]. Another explanation for the additive interaction be-
tween depression and CVD is related to AD pathology.
In the analysis of dementia subtypes, the interaction be-
tween depression and CVD was only associated with
AD. Although it requires cautious interpretation, we
hypothesize that the concurrence of vascular dysfunction
from CVD and AD pathology triggered by depression
initiates and aggravates clinically significant cognitive de-
cline. In a recent clinical study on CVD and AD path-
ology with 218 participants, CVD was not associated
with the rate of the beta-amyloid accumulation, but the
comorbidity of CVD and amyloid plaques accumulation
was associated with cognitive decline [44]. Chronic stress
and hypercortisolemia can induce beta-amyloid accumu-
lation, hyperphosphorylation of Tau proteins, and
neurotoxicity [45]. A prior study reported that depressed
patients have higher beta-amyloid aggregation levels
than healthy individuals [46]. The additive interaction of
depression and CVD on the dementia risk in our study
was more remarkable in women, who are known to be
at risk of AD [1]. Considering the age criteria (over 50
years) and common menopausal age in our study, the
sex effect seems to be explained not only by the role of
estrogen or other sex steroids alone, but also by
comprehensive sex differences in brain aging [47]. A
previous study that demonstrated the sex difference in
risk factors for the transition from mild cognitive im-
pairment to AD reported that severe periventricular
white matter hyperintensities and poorer global cogni-
tive function are the risk factors for men; however, de-
pressive symptoms and genetic burden of apolipoprotein
ε4 allele are the risk factors for women [48]. This result
implies that the correlation between depression and de-
mentia is different between men and women and is in
line with accumulating evidence for sex differences in
brain aging in our study. Further research is required to
discover the underlying neurobiology of sex differences
with respect to the effect of depression and CVD on
dementia.
Our findings indicate that individuals with depression
or CVD require thorough preventive approaches to
avoid another illness. Although treating depressive dis-
order might not change the course of a patient’s cogni-
tive decline [30], managing vascular risk factors and
preventing CVD in individuals with depression could re-
duce the incidence of dementia and personal and socio-
economic disease burdens. Women are known to have a
higher risk of depression; therefore, targeting this at-risk
population can also help the dementia prevention pol-
icies to work more effectively.
Limitations
This study has some limitations. The NHIS-NSC data-
base contains health insurance claims data and not diag-
nostic data [20]. Therefore, it is possible that the disease
diagnosis data used in this research were inaccurate,
which may have resulted in misclassification of patients
who did not seek treatment as healthy controls. We set
up strict operational definitions using multiple hospital
visits or drug prescription data in addition to the ICD-
10 codes to validate the diagnoses. However, these cri-
teria also cause a selection bias, so we would have acci-
dentally excluded “real” patients who did not visit
hospitals or missed their diagnosis owning to minimal
symptoms. Second, the characteristics of the cohort
could have influenced the results. The analyses were
based on individuals who benefited from the universal
healthcare system of South Korea; hence, our results
have limited generalizability for other ethnicities and
healthcare systems. Further, since the database did not
include non-insurance benefits data [11], we missed out
depressed patients who underwent non-pharmacological
treatments, such as cognitive-behavioral therapy. Indi-
viduals who are on medications for depression or cogni-
tive decline without being diagnosed can be considered
rare because it is not recommended to prescribe medica-
tions without a relevant ICD-10 diagnosis in South
Korea. Moreover, the prevalence of each disease in our
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sample was similar to that from other Korean registries
[49–51], and the HRs for depression [3, 30, 52, 53] and
CVD [54–57] were also similar to those previously re-
ported. Third, the identification of dementia etiologies
without biopsies or autopsies is complicated; therefore,
we had no choice but to determine the dementia sub-
types according to the initial codes of the main diagno-
ses for our analyses. Unfortunately, this method cannot
differentiate between clinically noteworthy dementia eti-
ologies that are not specified in a single ICD-10 code,
such as “mixed dementia.” Another limitation is that
possible confounding factors could be considered insuffi-
cient. Health-related behaviors, such as drinking and
smoking, are known to affect depression, CVD, and de-
mentia. They depend on age and sex; therefore, our find-
ings with regard to effect modification by age and sex
should be interpreted with caution. Finally, the selection
of patients with CVD may have led to survival bias,
which should be taken into account. Although CVD
mortality has significantly decreased over the last 3 de-
cades to 78% and 68% in men and women, respectively,
in South Korea [58], it is still one of the top causes of
mortality. However, CVD remains a great health burden
for each patient and society, and chronic treatment in-
cluding medication to prevent additional CVD for life-
long and rehabilitation to recover the function is
needed. Hence, CVD can be regarded as a chronic dis-
ease, and survivor-related research is important as well.
Conclusions
This nationwide, population-based cohort study demon-
strates that both depression and CVD, as well as their
interaction, are associated with an increased dementia
risk. To the best of our knowledge, this is the first study
to examine the coexistence effect of depression and
CVD on subsequent dementia risk, and we found posi-
tive additive interaction between depression and CVD
on the increased risk of dementia. Our results suggest
that individuals with depression or CVD need interven-
tions to prevent other conditions and that further inves-
tigation on the relevance of AD is required.
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